These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38539060)

  • 1. Haemophilia in the era of novel therapies: Where do inhibitors feature in the new landscape?
    Meeks SL; Zimowski KL
    Haemophilia; 2024 Apr; 30 Suppl 3():95-102. PubMed ID: 38539060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel.
    Escuriola-Ettingshausen C; Auerswald G; Königs C; Kurnik K; Scholz U; Klamroth R; Oldenburg J
    Haemophilia; 2021 May; 27(3):e305-e313. PubMed ID: 32937002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors: Diagnostic challenges, unknowns of inhibitor development, treatment of bleeding and surgery, and insights into diagnosis and treatment in China.
    Escuriola Ettingshausen C; Yang R; Wu W; Meeks SL
    Haemophilia; 2022 May; 28 Suppl 4():111-118. PubMed ID: 35521731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors.
    Jiménez-Yuste V; Auerswald G; Benson G; Dolan G; Hermans C; Lambert T; Ljung R; Morfini M; Santagostino E; Zupančić Šalek S
    Haemophilia; 2021 May; 27(3):340-350. PubMed ID: 33742707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologies.
    Mancuso ME; Croteau SE; Klamroth R
    Haemophilia; 2024 Apr; 30 Suppl 3():39-44. PubMed ID: 38481077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
    Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
    Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
    Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
    Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee.
    Collins PW; Liesner R; Makris M; Talks K; Chowdary P; Chalmers E; Hall G; Riddell A; Percy CL; Hay CR; Hart DP
    Haemophilia; 2018 May; 24(3):344-347. PubMed ID: 30070072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study.
    Janbain M; Enjolras N; Bolbos R; Brevet M; Bordet JC; Dargaud Y
    Haemophilia; 2021 Nov; 27(6):1002-1006. PubMed ID: 34644431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?
    Valentino LA; Ozelo MC; Herzog RW; Key NS; Pishko AM; Ragni MV; Samelson-Jones BJ; Lillicrap D
    J Thromb Haemost; 2023 Nov; 21(11):3033-3044. PubMed ID: 37225021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and cost of emicizumab prophylaxis in haemophilia A patients with inhibitors: A nationwide observational study in Taiwan.
    Shen MC; Chou SC; Chiou SS; Lin PC; Chen YC; Lin HY; Lee YC; Huang CE; Weng TF; Huang TH; Chung CY; Chen JS; Chen SH; Cheng SN; Hsiao CC; Huang YM; Chen SH; Yu YB; Lin SC; Lin CY; Peng CT; Wang JD;
    Haemophilia; 2023 Nov; 29(6):1499-1508. PubMed ID: 37819166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
    Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
    J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.
    Carcao M; Escuriola-Ettingshausen C; Santagostino E; Oldenburg J; Liesner R; Nolan B; Bátorová A; Haya S; Young G;
    Haemophilia; 2019 Jul; 25(4):676-684. PubMed ID: 31033112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
    Castaman G; Santoro C; Coppola A; Mancuso ME; Santoro RC; Bernardini S; Pugliese FR; Lubrano R; Golato M; Tripodi A; Rocino A; Santagostino E; ; Biasoli C; Borchiellini A; Catalano A; Contino L; Coluccia A; Cultrera D; De Cristofaro R; Di Minno G; Fabbri A; Franchini M; Gamba G; Giuffrida AC; Gresele P; Giampaolo A; Hassan HJ; Luciani M; Marchesini E; Marino R; Mazzucconi MG; Molinari AC; Morfini M; Notarangelo LD; Peccarisi L; Peyvandi F; Pollio B; Rivolta GF; Ruggieri MP; Sargentini V; Schiavoni M; Sciacovelli L; Serino ML; Siragusa S; Tagliaferri A; Testa S; Tosetto A; Zampogna S; Zanon E
    Blood Transfus; 2020 Mar; 18(2):143-151. PubMed ID: 31657709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of emicizumab in acquired hemophilia A: A case report.
    Yates SG; Webb CB; Sarode R; Ibrahim IF; Shen YP
    Transfus Apher Sci; 2022 Dec; 61(6):103457. PubMed ID: 35643753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.